Crizotinib targets in glioblastoma stem cells

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Glioblastoma stem cells (GSCs) drive tumor resistance and recurrence.
• Targeting GSCs is crucial for effective glioblastoma treatment.
• Crizotinib targets ALK, ROS1, and MET, approved for non-small-cell lung cancer.

Purpose of the Study:

• To investigate the status of ALK, ROS1, and MET in glioblastoma stem cells.
• To evaluate the potential of Crizotinib for eradicating GSCs.
• To explore the role of MET and ALK in GSC tumorigenicity.

Main Methods:

• Analysis of nine glioblastoma stem cell lines and their tumors.
• Fluorescent in situ hybridization (FISH) for genomic rearrangements/amplifications.
• Sanger sequencing for mutations and immunohistochemistry for protein expression.

Main Results:

• No significant ROS1 dysregulation observed.
• No ALK amplification/polysomy, but weak ALK overexpression in 3/9 GSCs.
• No MET amplification, but significant MET overexpression in 3/9 GSCs, especially in mesenchymal subtypes.
• No ALK or MET mutations detected.

Conclusions:

• Molecular rearrangements of ALK, ROS1, and MET were not found, questioning Crizotinib efficacy for GSC eradication.
• MET overexpression in mesenchymal GSCs and ALK overexpression in some GSCs suggest their involvement in tumorigenicity.
• Further investigation into MET and ALK roles in GSC tumorigenesis is warranted.